Kabazitaksel (Cabazitaxel 2-Propanol Solvate)

Kabazitaksel (cabazitaxel) is employed in the management of prostate cancer that no longer responds to hormonal therapy.

• Metastatic castration‑resistant prostate cancer: improves overall survival and delays disease progression.
• Post‑docetaxel disease progression: provides an alternative taxane option after failure of first‑line taxane therapy.
• Hormone‑refractory prostate cancer: offers cytotoxic activity when androgen‑deprivation therapy is ineffective.

• Cabazitaxel binds to the β‑tubulin subunit of microtubules, promoting polymerization and preventing depolymerization. This stabilizes microtubule networks, disrupts mitotic spindle formation, and arrests cells in the G2/M phase of the cell cycle, leading to apoptosis of rapidly dividing tumor cells. The drug achieves intracellular concentrations that overcome P‑glycoprotein–mediated efflux, a common resistance mechanism to earlier taxanes, thereby retaining activity in tumors previously exposed to docetaxel.

Cabazitaxel therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: decreased white blood cell count increasing infection risk.
• Fatigue: generalized tiredness affecting daily activities.
• Diarrhea: watery stools that may lead to dehydration.
• Nausea: sensation of urge to vomit.
• Alopecia: hair loss on scalp and body.
• Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Cardiac toxicity: arrhythmias or reduced left ventricular function.
• Hepatotoxicity: elevated liver enzymes or liver failure.
• Severe mucositis: painful inflammation of the mouth and gastrointestinal tract.

When using Kabazitaksel, clinicians should observe specific safety measures to minimize risks.

• Baseline blood counts: obtain complete blood count before each cycle to monitor neutropenia.
• Infection monitoring: watch for signs of fever or infection and treat promptly.
• Liver function: assess hepatic enzymes prior to treatment and during therapy.
• Concomitant drugs: avoid concurrent use of strong CYP3A4 inhibitors that may increase exposure.
• Pregnancy and lactation: contraindicated in pregnant or breastfeeding women due to potential fetal harm.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines, requiring careful assessment before co‑administration.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise cabazitaxel plasma levels and increase toxicity.
• Concurrent use with other myelosuppressive agents: can exacerbate neutropenia and thrombocytopenia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure and efficacy.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential increased bleeding risk.
• Antiemetics containing corticosteroids: may affect immune response; observe for infection signs.